Samir Parekh, MD

Assistant Professor of Medicine

Department of Medicine

Office: 1365B Clifton Rd

Phone: 404-778-3986

Fax: 404-778-2925



Emory Healthcare clinical profile

Dr. Parekh serves as The Emory Clinic Director of Hepatology Clinical Operations. He completed his internal medicine residency followed by fellowships in gastroenterology and transplant hepatology at Emory University. He then joined the Emory hepatology faculty in 2007 and shortly after established Emory’s first board accredited transplant hepatology fellowship,which he currently serves as Fellowship Program Director. Dr. Parekh earned a Certificate of Added Qualification in Transplant Hepatology in 2010.

Medical School: Medical College of Ohio
Internship: Emory University School of Medicine
Residency: Emory University School of Medicine
Gastroenterology Fellowship: Emory University School of Medicine
Hepatology Fellowship: Emory University School of Medicine

American Board of Internal Medicine Certifications:
Gastroenterology: 2007
Internal Medicine: 2003
Hepatology: 2010


Specialties: Gastroenterology and Hepatology
Areas of Clinical Interest: Nonalcoholic fatty liver disease; Autoimmune liver disease; Viral hepatitis; Liver transplantation


Organizational Memberships:
American Society of the Study of Liver Disease
American Society of Transplantation


* Parekh S, Spivey JR. Recurrent Liver Disease. In: Textbook of Organ Transplantation, 2014.

* Elder RW, Parekh S, Book WM. More on hepatocellular carcinoma after the Fontan procedure. N Engl J Med. 2013 Aug 1;369(5):490.

* Karsan H, Parekh S. Management of Alcoholic Hepatitis. World J Hepatol. 2012 Dec 27;4(12):335-41.

* Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, Martin LG, Kim HS. Transjugular Intrahepatic Portosystemic Shunt for Symptomatic
Refractory Hepatic Hydrothorax in Patients With Cirrhosis. Am J Gastroenterol. 2010 Mar;105(3):635-41.

* Parekh S, Anania FA. Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease. Gastroenterology. 2007;132:2191-2207.

Clinical Trials:
* Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with
Non-Alcoholic Steatohepatitis (NASH)